Less than one in 10 individuals that would benefit from obesity jabs like Wegovy have access to them, states the World Health Organization as it releases its first guidance on the medications.
Given more than one billion individuals worldwide currently classified as obese, it is advocating for more widespread and fairer availability to GLP-1 medication.
Per estimates, more than two billion could be obese by 2030 without intervention.
"The new guidelines recognises that excess weight is a long-term condition that can be treated with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and supply-chain constraints are significant hurdles to widespread availability to the injections that can help people shift significant body mass, explains the body.
Weight-Loss Drug Scarcity
Despite the present best projected case, the manufacturing of these medications would only suffice for around 100 million people – fewer than 10% of the global need, according to the health organization.
The advice calls on countries and companies to increase availability, by approaches including patent sharing.
A patent on a key compound – the core component of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
The Way Obesity Drugs Work
GLP-1 drugs imitate a biological compound to slow digestion, curb appetite and increase feelings of fullness so people reduce food intake.
Individuals usually start to lose weight within a few weeks of starting on the regular doses.
Studies suggests users may put most of the weight back on a year later of discontinuing the drug, because their normal appetite come back.
Being carrying excess weight elevates your likelihood for experiencing medical conditions, including diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the WHO.
